Prelude Capital Management’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Prelude Capital Management’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,500	Closed	-$128K	–	2132
2020 Q3	$128K	Hold	2,500	–	–	0.01%	826
2020 Q2	$149K	Buy	+2,500	New	+$134K	0.01%	823
2019 Q3	–	Sell	-266	Closed	-$6K	–	2150
2019 Q2	$6K	Buy	266 +190	+250%	+$4.45K	﹤0.01%	1512
2019 Q1	$2K	Buy	+76	New	+$1.99K	﹤0.01%	1690
2017 Q4	–	Sell	-1,613	Closed	-$31K	–	1786
2017 Q3	$31K	Buy	+1,613	New	+$29.6K	﹤0.01%	1231

Other funds holding DCPH

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Prelude Capital Management's DCPH Position: Q4 2020 in Review

Prelude Capital Management sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q4 2020, closing a stake of 2,500 shares — an estimated $128K sold.

Prelude Capital Management first reported a position in DCPH in Q3 2017 and held it in 5 quarters. The position peaked at $149K in Q2 2020. 182 funds tracked by Wall St. Rank hold DCPH as of Q4 2020.

Prelude Capital Management reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
Prelude Capital Management sold 2,500 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q4 2020, an estimated $128K.
Prelude Capital Management first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 5 quarters.
Prelude Capital Management's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $149K in Q2 2020.
182 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q4 2020.

Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.